Pioglitazone ameliorates memory deficits in streptozotocin-induced diabetic mice by reducing brain β-amyloid through PPARγ activation

Acta Pharmacologica Sinica

Volumn 34, Issue 4, 2013, Pages 455-463

  Liu, Li Ping ^a   Yan, Tian Hua ^b   Jiang, Li Ying ^b   Hu, Wei ^a   Hu, Meng ^b   Wang, Chao ^b   Zhang, Qian ^a   Long, Yan ^b   Wang, Jiang Qing ^b   Li, Yong Qi ^b   Hu, Mei ^b   Hong, Hao ^b  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

amyloid; APP; BACE1; Cortex; Diabetes mellitus; Hippocampus; Learning memory; NF B; Pioglitazone; PPAR ; Receptor for advanced glycation end products

Indexed keywords

AMYLOID PRECURSOR PROTEIN; BETA SECRETASE; BETA SECRETASE 1; GLUCOSE; GLUCOSE OXIDASE; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PIOGLITAZONE; STREPTOZOCIN; TRANSCRIPTION FACTOR RELA;

AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; COGNITION; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GLUCOSE BLOOD LEVEL; HIPPOCAMPUS; HYPERGLYCEMIA; HYPOINSULINEMIA; INSULIN BLOOD LEVEL; MALE; MAZE TEST; MOUSE; NONHUMAN; PASSIVE AVOIDANCE; PROTEIN EXPRESSION; STREPTOZOCIN DIABETES; TREATMENT DURATION; WESTERN BLOTTING;

AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ASPARTIC ACID ENDOPEPTIDASES; BLOOD GLUCOSE; BODY WEIGHT; CEREBRAL CORTEX; COGNITION; DIABETES MELLITUS, EXPERIMENTAL; HIPPOCAMPUS; INSULIN; MALE; MEMORY DISORDERS; MICE; MICE, INBRED ICR; NF-KAPPA B; PPAR GAMMA; RANDOM ALLOCATION; RECEPTORS, IMMUNOLOGIC; THIAZOLIDINEDIONES;

EID: 84877310015     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2013.11     Document Type: Article

References (39)

1. Biessels GJ, Deary IJ, Ryan CM. Cognition and diabetes: A lifespan perspective. Lancet Neurol 2008; 7: 84-90
2. Kodl CT, Seaquist ER. Cognitive dysfunction and diabetes mellitus. Endocr Rev 2008; 29: 494-511 (Pubitemid 351831510)
3. Wrighten SA, Piroli GG, Grillo CA, Reagan LP. A look inside the diabetic brain: Contributors to diabetes-induced brain aging. Biochim Biophys Acta 2009; 1792: 444-53
4. Biessels GJ, Kamal A, Urban IJ, Spruijt BM, Erkelens DW, Gispen WH. Water maze learning and hippocampal synaptic plasticity in streptozotocin-diabetic rats: Effects of insulin treatment. Brain Res 1998; 800: 125-35 (Pubitemid 28361929)
5. Biessels GJ, Cristino NA, Rutten GJ, Hamers FP, Erkelens DW, Gispen WH. Neurophysiological changes in the central and peripheral nervous system of streptozotocin-diabetic rats: Course of development and effects of insulin treatment. Brain 1999; 122: 757-68 (Pubitemid 29158781)
6. Sima AA, Li ZG. The effect of C-peptide on cognitive dysfunction and hippocampal apoptosis in type 1 diabetic rats. Diabetes 2005; 54: 1497-505 (Pubitemid 40586682)
7. Sima AA, Zhang W, Muzik O, Kreipke CW, Rafols JA, Hoffman WH. Sequential abnormalities in type 1 diabetic encephalopathy and the effects of C-Peptide. Rev Diabet Stud 2009; 6: 211-22
8. Sims-Robinson C, Kim B, Rosko A, Feldman EL. How does diabetes accelerate Alzheimer disease pathology? Nat Rev Neurol 2010; 6: 551-9
9. Peila R, Rodriguez BL, Launer LJ, Honolulu-Asia Aging Study. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes 2002; 51: 1256-62 (Pubitemid 34438377)
10. Valente T, Gella A, Fernàndez-Busquets X, Unzeta M, Durany N. Immunohistochemical analysis of human brain suggests pathological synergism of Alzheimer's disease and diabetes mellitus. Neurobiol Dis 2010; 37: 67-76
11. Li ZG, Zhang W, Sima AA. Alzheimer-like changes in rat models of spontaneous diabetes. Diabetes 2007; 56: 1817-24 (Pubitemid 47025451)
12. Hong H, Liu LP, Liao JM, Wang TS, Ye FY, Wu J, et al. Downregulation of LRP1 at the blood-brain barrier in streptozotocin-induced diabetic mice. Neuropharmacology 2009; 56: 1054-9
13. Jolivalt CG, Hurford R, Lee CA, Dumaop W, Rockenstein E, Masliah E. Type 1 diabetes exaggerates features of Alzheimer's disease in APP transgenic mice. Exp Neurol 2010; 223: 422-31
14. Liu Y, Liu H, Yang J, Liu X, Lu S, Wen T, et al. Increased amyloid betapeptide (1-40) level in brain of streptozotocin-induced diabetic rats. Neurosci 2008; 153: 796-802
15. Qu ZS, Tian Q, Zhou XW, Wang XC, Wang Q, Zhang Q, et al. Alteration of beta-Amyloid and glutamate transporter in the brain of diabetes rats and the underlying mechanism. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2005; 27: 708-11
16. Shuli S, Yongmei Z, Zhiwei Z, Zhijuan J. beta-Amyloid and its binding protein in the hippocampus of diabetic mice: Effect of APP17 peptide. Neuroreport 2001; 12: 3317-9 (Pubitemid 33010664)
17. Takeda S, Sato N, Uchio-Yamada K, Sawada K, Kunieda T, Takeuchi D, et al. Diabetes-Accelerated memory dysfunction via cerebrovascular inflammation and Abeta deposition in an Alzheimer mouse model with diabetes. Proc Natl Acad Sci U S A 2010; 107: 7036-41
18. Sood V, Colleran K, Burge MR. Thiazolidinediones: A comparative review of approved uses. Diabetes Technol Ther 2000; 2: 429-40
19. Nicolakakis N, Hamel E. The nuclear receptor PPARgamma as a therapeutic target for cerebrovascular and brain dysfunction in Alzheimer's disease. Front Aging Neurosci 2010; 2: 21-6
20. Jiang LY, Tang SS, Wang XY, Liu LP, Long Y, Hu M, et al. PPARγ agonist pioglitazone reverses memory impairment and biochemical changes in a mouse model of type 2 diabetes mellitus. CNS Neurosci Ther 2012; 18: 659-66
21. Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 1984; 11: 47-60 (Pubitemid 14088970)
22. Karran E, Mercken M, De Strooper B. The amyloid cascade hypothesis for Alzheimer's disease: An appraisal for the development of therapeutics. Nat Rev Drug Discov 2011; 10: 698-712
23. Rincon N, Xu K, Li J, Martinez JA, Hernandez MA, Singh GS, et al. Blockade of receptor for advanced glycation end products in a model of type 1 diabetic leukoencephalopathy. Diabetes 2012. DOI: 10.2337/db12-0317
24. Chami L, Buggia-Prévot V, Duplan E, Delprete D, Chami M, Peyron JF, et al. Nuclear factor-κB regulates βAPP and β-And γ-secretases differently at physiological and supraphysiological Aβ concentrations. J Biol Chem 2012; 287: 24573-84
25. Brands AM, Kessels RP, Hoogma RP, Henselmans JM, van der Beek Boter JW, Kappelle LJ, et al. Cognitive performance, psychological well-being, and brain magnetic resonance imaging in older patients with type 1 diabetes. Diabetes 2006; 55: 1800-6 (Pubitemid 44324135)
26. Hannonen R, Komulainen J, Eklund K, Tolvanen A, Riikonen R, Ahonen T. Verbal and academic skills in children with early-onset type 1 diabetes. Dev Med Child Neurol 2010; 52: E143-7
27. Munshi M, Grande L, Hayes M, Ayres D, Suhl E, Capelson R, et al. Cognitive dysfunction is associated with poor diabetes control in older adults. Diabetes Care 2006; 29: 1794-9 (Pubitemid 44156632)
28. Glabe CG. Common mechanisms of amyloid oligomer pathogenesis in degenerative disease. Neurobiol Aging 2006; 27: 570-5 (Pubitemid 43290525)
29. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer's disease. Lancet 2011; 377: 1019-31
30. Han W, Li C. Linking type 2 diabetes and Alzheimer's disease. Proc Natl Acad Sci U S A 2010; 107: 6557-8
31. Jung SW, Han OK, Kim SJ. Increased expression of β amyloid precursor gene in the hippocampus of streptozotocin-induced diabetic mice with memory deficit and anxiety induction. Neural Transm 2010; 117: 1411-8
32. Guglielmotto M, Aragno M, Tamagno E, Vercellinatto I, Visentin S, Medana C, et al. AGEs/RAGE complex upregulates BACE1 via NF-kappaB pathway activation. Neurobiol Aging 2012; 33: 196.e13-27
33. Bourne KZ, Ferrari DC, Lange-Dohna C, Rossner S, Wood TG, Perez-Polo Jr. Differential regulation of BACE1 promoter activity by nuclear factor-B in neurons and glia upon exposure to beta-Amyloid peptides. J Neurosci Res 2007; 85: 1194-204 (Pubitemid 46724363)
34. Bucala R, Cerami A. Advanced glycosylation: Chemistry, biology, and implications for diabetes and aging. Adv Pharmacol 1992; 23: 1-34
35. Thorpe SR, Baynes JW. Maillard reaction products in tissue proteins: New products and new perspectives. Amino Acids 2003; 25: 275-81 (Pubitemid 38041265)
36. Yamagishi S, Matsui T, Nakamura K. Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes. Curr Drug Targets 2007; 8: 1138-43 (Pubitemid 47578142)
37. Liu LP, Hong H, Liao JM, Wang TS, Wu J, Chen SS, et al. Upregulation of RAGE at the blood-brain barrier in streptozotocin-induced diabetic mice. Synapse 2009; 63: 636-42
38. Mandrekar-Colucci S, Landreth GE. Nuclear receptors as therapeutic targets for Alzheimer's disease. Expert Opin Ther Target 2011; 15: 1085-97
39. Pascual G, Fong AL, Ogawa S, Gamliel A, Li AC, Perissi V, et al. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature 2005; 437: 759-63 (Pubitemid 41486547)